Clinical efficacy of adjuvant treatment with PD-1 inhibitors for hepatocellular carcinoma after microwave ablation

HOU Xiao-wei; QIN Xiu-ju; ZHUANG Xing-jun; CHEN Xin; WEI Li

doi:10.11659/jjssx.10E023057

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy of adjuvant treatment with PD-1 inhibitors for hepatocellular carcinoma after microwave ablation

Gastroenterology and Hepatobiliology | 更新时间：2024-11-18

- Clinical efficacy of adjuvant treatment with PD-1 inhibitors for hepatocellular carcinoma after microwave ablation
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 33, Issue 11, Pages: 970-974(2024)
- 作者机构：
  
  中国人民解放军海军第九七一医院肿瘤科，山东青岛 266071
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.10E023057
  CLC： R453.9;R735.7
- Published：25 November 2024，
  
  Received：13 October 2023，
- 稿件说明：
移动端阅览
侯晓玮,秦秀菊,庄兴俊等.微波消融术后辅助PD-1抑制剂治疗肝细胞癌的临床疗效[J].局解手术学杂志,2024,33(11):970-974.

HOU Xiao-wei,QIN Xiu-ju,ZHUANG Xing-jun,et al.Clinical efficacy of adjuvant treatment with PD-1 inhibitors for hepatocellular carcinoma after microwave ablation[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):970-974.
侯晓玮,秦秀菊,庄兴俊等.微波消融术后辅助PD-1抑制剂治疗肝细胞癌的临床疗效[J].局解手术学杂志,2024,33(11):970-974. DOI： 10.11659/jjssx.10E023057.

HOU Xiao-wei,QIN Xiu-ju,ZHUANG Xing-jun,et al.Clinical efficacy of adjuvant treatment with PD-1 inhibitors for hepatocellular carcinoma after microwave ablation[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):970-974. DOI： 10.11659/jjssx.10E023057.

摘要

目的

观察微波消融术后辅助PD-1抑制剂治疗肝细胞癌患者的临床疗效和治疗前后患者淋巴细胞亚群的变化。

方法

纳入我院56例接受微波消融术的肝细胞癌患者，根据治疗方法不同分为2组，每组28例。其中A组患者采用微波消融术后辅助PD-1抑制剂治疗；B组患者单纯行微波消融术。观察微波消融术的局部疗效、辅助PD-1抑制剂治疗后患者生存情况及相关不良反应发生情况。采集患者外周静脉血，分别检测2组患者微波消融术前、B组患者微波消融术后及A组患者6周期免疫治疗后淋巴细胞亚群数量。

结果

A组病例完全消融率与B组比较差异无统计学意义（89.3%

vs.

85.7%，

=0.69），A组病灶完全消融率与B组比较差异无统计学意义（91.7%

vs.

85.3%，

=0.40）。A组患者的中位无进展生存期（mPFS）尚未达到，B组患者的mPFS为12.6个月，2组患者mPFS比较，差异有统计学意义（

=0.03）；2组患者中位总生存期（mOS）均未达到。治疗后A组患者CD

T淋巴细胞比例较B组患者明显升高[（37.05±2.22）%

vs.

（29.23±2.88）%，

=0.03

]

，CD

T淋巴细胞比例[（21.08±2.23）%

vs.

（27.18±1.75）%，

=0.04

]

和调节T细胞（Treg细胞）比例[（4.26±0.31）%

vs.

（5.22±0.34）%，

=0.04

]

明显下降。所有患者微波消融术后均未出现严重不良反应，A组28例患者行PD-1抑制剂治疗后均未出现3级以上不良反应。

结论

微波消融术后辅助PD-1抑制剂治疗能够延长患者的无进展生存期，强化患者T淋巴细胞的功能，削弱免疫抑制性细胞的作用，其可能是延缓肝癌微波消融术后复发的一种有效策略。

Abstract

Objective

To observe the clinical efficacy of adjuvant PD-1 inhibitor in the treatment of patients with hepatocellular carcinoma after microwave ablation and the changes of lymphocyte subsets before and after treatment.

Methods

A total of 56 patients with hepatocellular carcinoma who underwent microwave ablation in our hospital were randomly divided into two groups according to different treatments，with 28 cases in each group. Patients in the group A received adjuvant treatment with PD-1 inhibitors after microwave ablation，while patients in the group B received microwave ablation alone. The local efficacy of microwave ablation，the survival of patients after adjuvant treatment of PD-1 inhibitor and the occurrence of related adverse reactions were observed. Peripheral venous blood was collected to detect the number of T lymphocyte subsets before microwave ablation in the two groups，after microwave ablation in the group B，and after six cycles of immunotherapy in the group A.

Results

There was no significant difference in the complete ablation rate of cases between group A and group B （89.3%

vs.

85.7%，

=0.69），and there was no significant difference in the complete ablation rate of lesions between group A and group B （91.7%

vs.

85.3%，

=0.40）. The median progression-free survival （mPFS） of the group A was not yet reached，the mPFS of group B was 12.6 months，and there was a statistically significant difference in the mPFS between the two groups（

=0.03）.The median overall survival （mOS） of the two group were not yet reached. The proportion of CD

T lymphocytes after treatment in the group A significantly increased compared with that in the group B ［（37.05±2.22）%

vs.

（29.23±2.88）%，

=0.03］，while the proportion of CD

T lymphocytes ［（21.08±2.23）%

vs.

（27.18±1.75）%，

=0.04）］ and the proportion of Treg cells［（4.26±0.31）%

vs.

（5.22±0.34）%，

=0.04］ significantly decreased. Ther

e was no serious adverse reactions in all patients after microwave ablation，and 28 patients in the group A had no adverse reactions above grade 3 after PD-1 inhibitor treatment.

Conclusion

Adjuvant PD-1 inhibitor therapy after microwave ablation can prolong the progression-free survival of patients，enhance the function of T lymphocytes，and weaken the role of immunosuppressive cells，which may be an effective strategy to delay the recurrence of liver cancer after microwave ablation.

关键词

微波消融PD-1抑制剂肝细胞癌淋巴细胞亚群

Keywords

microwave ablationPD-1 inhibitorhepatocellular carcinomalymphocyte subsets

references

Zhang SW，Sun KX，Zheng RS，et al.Cancer incidence and mortality in China，2015［J］.J National Cancer Center，2021，1（1）：2-11.doi：10.1016/j.jncc.2020.12.001http://dx.doi.org/10.1016/j.jncc.2020.12.001.

蔡建强，赵宏，陈晓.肝癌综合治疗新格局［J］.中华消化外科杂志，2024，23（2）：204-208.doi：10.3760/cma.j.cn115610-20231208-00243http://dx.doi.org/10.3760/cma.j.cn115610-20231208-00243.

den Brok MH，Sutmuller RP，van der Voort R，et al.In situ tumor ablation creates an antigen source for the generate on of antitumor immunity［J］.Cancer Res，2004，64（11）：4024-4029.doi： 10.1158/0008-5472.CAN-03-3949http://dx.doi.org/10.1158/0008-5472.CAN-03-3949.

Yu Z，Geng J，Zhang M，et al.Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death ［J］.Oncotarget，2014，5（15）：6526-6539.doi： 10.18632/oncotarget.2310http://dx.doi.org/10.18632/oncotarget.2310.

Dong BW，Zhang J，Liang P，et al.Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma［J］.Int J Hyperthermia，2003，19（2）：119-133.doi： 10.1080/0265673021000017154http://dx.doi.org/10.1080/0265673021000017154.

Liang SC，Latchman YE，Buhlmann JE，et al.Regulation of PD-1，PD-L1，and PD-L2 expression during normal and autoimmune responses［J］.Eur J Immunol，2003，33（10）：2706-2716.doi：10.1002/eji.200324228http://dx.doi.org/10.1002/eji.200324228.

Villanueva A.Hepatocellular carcinoma［J］.N Engl J Med，2019，380：1450-1462.doi： 10.1056/NEJMra1713263http://dx.doi.org/10.1056/NEJMra1713263.

肝癌术后辅助治疗中国专家共识协作组.肝癌术后辅助治疗中国专家共识（2023版）［J］.中华消化外科杂志，2023，22（12）：437-448.doi：10.3760/cma.j.cn112139-20230914-00121http://dx.doi.org/10.3760/cma.j.cn112139-20230914-00121.

Wiowski TT，Hänsler J，Neureiter D，et al.Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits［J］.Cancer Res，2003，63（19）：6496-6500.

Liang P，Dong B，Yu X，et al.Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation［J］.Radiology，2005，235（1）：299-307.doi： 10.1148/radiol.2351031944http://dx.doi.org/10.1148/radiol.2351031944.

Wei Z，Yang X，Ye X，et al.Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer［J］.J Cancer Res Ther，2019，15（7）：1629-1634. doi： 10.4103/jcrt.JCRT_990_19http://dx.doi.org/10.4103/jcrt.JCRT_990_19.

Leuchte K，Staib E，Thelen M，et al.Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma［J］.Cancer Immunol Immunother，2021，70（4）：893-907.doi：10.1007/s00262-020-02734-1http://dx.doi.org/10.1007/s00262-020-02734-1.

Wang K，Wang C，Jiang H，et al.Combination of ablation and immunotherapy for hepatocellular carcinoma：where we are and where to go［J］.Front Immunol，2021，12：792781.doi：10.3389/fimmu.2021.792781http://dx.doi.org/10.3389/fimmu.2021.792781.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of aerobic glycolysis in liver cancer

Clinical significance of FEN1 regulating the occurrence and prognosis of hepatocellular carcinoma

Significance of different preoperative nutritional scoring systems in prognosis evaluation of radical resection of hepatocellular carcinoma

Clinical application of microwave ablation in treatment of severe traumatic liver rupture

Study in L-carnosine on the proliferation and apoptosis of human hepatocellular carcinoma HepG2 cells

Related Author

ZHANG Zhi-qing

WANG Qiang

CHEN Feng

YANG Zhi-yong

CEN Hong-bing

ZHAO Jian-hong

TU Cong-yin

HU Kong-wang

Related Institution

Department of General Surgery， Zhoucun People’s Hospital of Zibo City in Shandong Provence

Department of Hepatobiliary and Pancreatic Surgery，Third Affiliated Hospital of Chongqing Medical University

Department of Pathology，Huanggang Central Hospital Affiliated to Changjiang University

Department of Oncology，Huanggang Central Hospital Affiliated to Changjiang University

Department of Hepatobiliary Surgery，Huanggang Central Hospital Affiliated to Changjiang University

⁰